标题
Targeting EphA2 in cancer
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-08-18
DOI
10.1186/s13045-020-00944-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level
- (2020) Jing Mo et al. CELLULAR ONCOLOGY
- Roles of EphA1/A2 and ephrin-A1 in cancer
- (2019) Katsuaki Ieguchi et al. CANCER SCIENCE
- EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer.
- (2019) Giulia Martini et al. MOLECULAR CANCER THERAPEUTICS
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors
- (2019) Kohei Shitara et al. Journal for ImmunoTherapy of Cancer
- EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma
- (2019) Yige Fu et al. Pharmaceutics
- Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer
- (2019) HIROFUMI KUROSE et al. ANTICANCER RESEARCH
- Synergy between EphA2-ILs-DTXp, a novel EphA2 targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models
- (2019) Walid S. Kamoun et al. MOLECULAR CANCER THERAPEUTICS
- Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice
- (2019) Francesca Ferlenghi et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells
- (2018) ATSUSHI SAKAMOTO et al. ANTICANCER RESEARCH
- Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation
- (2018) Yuho Hamaoka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma
- (2018) Silvia Garcia-Monclús et al. INTERNATIONAL JOURNAL OF CANCER
- Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer
- (2018) Ning Li et al. Translational Oncology
- UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice
- (2018) Claudio Festuccia et al. Oncotarget
- EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma
- (2018) Hui Shi et al. Journal of Thoracic Disease
- Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
- (2018) Zhongzhen Yi et al. Molecular Therapy-Methods & Clinical Development
- Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer
- (2018) Tao Zhang et al. EBioMedicine
- Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
- (2017) Michael J. Wagner et al. MOLECULAR CANCER THERAPEUTICS
- First approval in sight for Novartis' CAR-T therapy after panel vote
- (2017) Cormac Sheridan NATURE BIOTECHNOLOGY
- EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells
- (2017) Elisabet Cuyàs et al. ONCOLOGY REPORTS
- Recent progress in development of siRNA delivery vehicles for cancer therapy
- (2016) Hyun Jin Kim et al. ADVANCED DRUG DELIVERY REVIEWS
- Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis
- (2016) Carmine Giorgio et al. BIOCHEMICAL PHARMACOLOGY
- Novel anti-EPHA2 antibody, DS-8895a for cancer treatment
- (2016) Jun Hasegawa et al. CANCER BIOLOGY & THERAPY
- EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
- (2016) Katherine R. Amato et al. CANCER RESEARCH
- The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer
- (2016) Victoria M. Youngblood et al. CANCER RESEARCH
- Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a
- (2016) I. J. G. Burvenich et al. JOURNAL OF NUCLEAR MEDICINE
- Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting
- (2016) Melissa L. Geddie et al. mAbs
- Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
- (2015) David J. DiLillo et al. CELL
- Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph–ephrin system
- (2015) Riccardo Castelli et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy
- (2015) Mahesh Jonnalagadda et al. MOLECULAR THERAPY
- Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
- (2015) D. J. DiLillo et al. Cancer Immunology Research
- UniPR129 is a competitive small molecule Eph-ephrin antagonist blockingin vitroangiogenesis at low micromolar concentrations
- (2014) I Hassan-Mohamed et al. BRITISH JOURNAL OF PHARMACOLOGY
- Generation and characterization of a single-chain anti-EphA2 antibody
- (2014) Yehuda Goldgur et al. GROWTH FACTORS
- Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC
- (2014) Katherine R. Amato et al. JOURNAL OF CLINICAL INVESTIGATION
- The immunomodulatory effect of propolis on receptors expression, cytokine production and fungicidal activity of human monocytes
- (2014) Michelle Cristiane Búfalo et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein-Protein Antagonists
- (2013) Massimiliano Tognolini et al. ChemMedChem
- CAR T cells: driving the road from the laboratory to the clinic
- (2013) Eleanor J. Cheadle et al. IMMUNOLOGICAL REVIEWS
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- Amino Acid Conjugates of Lithocholic Acid As Antagonists of the EphA2 Receptor
- (2013) Matteo Incerti et al. JOURNAL OF MEDICINAL CHEMISTRY
- Eph Receptor Signaling and Ephrins
- (2013) E. M. Lisabeth et al. Cold Spring Harbor Perspectives in Biology
- Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene
- (2012) Bhagyalaxmi Sukka-Ganesh et al. BMC CANCER
- Structure-Activity Relationships and Mechanism of Action of Eph-ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor
- (2012) Massimiliano Tognolini et al. ChemMedChem
- Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
- (2012) Christina M. Annunziata et al. INVESTIGATIONAL NEW DRUGS
- Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
- (2012) Geoffrey Porez et al. JOURNAL OF LIPID RESEARCH
- Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells
- (2012) Si Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
- (2012) Kevin KH Chow et al. MOLECULAR THERAPY
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- EphA2 Receptor Activation by Monomeric Ephrin-A1 on Supported Membranes
- (2011) Qian Xu et al. BIOPHYSICAL JOURNAL
- A Disalicylic Acid-Furanyl Derivative Inhibits Ephrin Binding to a Subset of Eph Receptors
- (2011) Roberta Noberini et al. Chemical Biology & Drug Design
- EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
- (2011) RONG Biao-xue et al. CURRENT CANCER DRUG TARGETS
- Polyphenol rich botanicals used as food supplements interfere with EphA2–ephrinA1 system
- (2011) Iftiin Hassan Mohamed et al. PHARMACOLOGICAL RESEARCH
- Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation
- (2011) Carmine Giorgio et al. PLoS One
- EphA receptor signaling—Complexity and emerging themes
- (2011) Hui Miao et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma
- (2010) J. W. Lee et al. CLINICAL CANCER RESEARCH
- Emerging strategies for EphA2 receptor targeting for cancer therapeutics
- (2010) Manish Tandon et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- EphA2Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation
- (2010) Leonardo Faoro et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Architecture of Eph receptor clusters
- (2010) J. P. Himanen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors
- (2009) Yongmun Choi et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt
- (2009) Hui Miao et al. CANCER CELL
- EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma
- (2009) Jeong-Won Lee et al. JNCI-Journal of the National Cancer Institute
- Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
- (2008) Q Chang et al. BRITISH JOURNAL OF CANCER
- Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity
- (2008) Shinjiro Yamaguchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo
- (2008) D. Jackson et al. CANCER RESEARCH
- Eph-Ephrin Bidirectional Signaling in Physiology and Disease
- (2008) Elena B. Pasquale CELL
- Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
- (2008) R. Buettner et al. MOLECULAR CANCER RESEARCH
- The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
- (2008) J. Wykosky et al. MOLECULAR CANCER RESEARCH
- Targeting bile-acid signalling for metabolic diseases
- (2008) Charles Thomas et al. NATURE REVIEWS DRUG DISCOVERY
- Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor
- (2008) J Wykosky et al. ONCOGENE
- RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells
- (2008) Zhangming Zhou et al. SURGICAL NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More